Browse MUC16

Summary
SymbolMUC16
Namemucin 16, cell surface associated
Aliases FLJ14303; CA125 ovarian cancer antigen; ovarian cancer-related tumor marker CA125; ovarian carcinoma antigen ......
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Single-pass type I membrane protein. Secreted, extracellular space. Note=May be liberated into the extracellular space following the phosphorylation of the intracellular C-terminus which induces the proteolytic cleavage and liberation of the extracellular domain.
Domain PF01390 SEA domain
Function

Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.

> Gene Ontology
 
Biological Process GO:0006486 protein glycosylation
GO:0006493 protein O-linked glycosylation
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0016266 O-glycan processing
GO:0043413 macromolecule glycosylation
GO:0070085 glycosylation
Molecular Function -
Cellular Component GO:0005796 Golgi lumen
GO:0019898 extrinsic component of membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-5621481: C-type lectin receptors (CLRs)
R-HSA-5621480: Dectin-2 family
R-HSA-5083632: Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS)
R-HSA-5083636: Defective GALNT12 causes colorectal cancer 1 (CRCS1)
R-HSA-5083625: Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC)
R-HSA-1643685: Disease
R-HSA-3906995: Diseases associated with O-glycosylation of proteins
R-HSA-3781865: Diseases of glycosylation
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-392499: Metabolism of proteins
R-HSA-5173105: O-linked glycosylation
R-HSA-913709: O-linked glycosylation of mucins
R-HSA-597592: Post-translational protein modification
R-HSA-977068: Termination of O-glycan biosynthesis
Summary
SymbolMUC16
Namemucin 16, cell surface associated
Aliases FLJ14303; CA125 ovarian cancer antigen; ovarian cancer-related tumor marker CA125; ovarian carcinoma antigen ......
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MUC16 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between MUC16 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
24886523Ovarian CarcinomaInhibit immunityThe importance of MUC16/CA125 in the diagnosis, progression and therapy of ovarian cancer warrants the need for in-depth research on the biochemistry and biology of this mucin.
16126266Ovarian NeoplasmInhibit immunity (T cell function)CA125 was isolated from OVCAR-3 cells and its purity was determined by ELISA and ultra-sensitive mass spectrometric analysis. NK cells incubated with CA125 for 72 h exhibited a 50-70% decrease in the lysis of K562 targets. Inhibition of NK function was observed at CA125 concentrations (10,000-100,000 U/ml) that are expected to be significantly lower than those observed in the tumor microenvironment. CA125 did, however, induce major downregulation of CD16 and minor decrease in expression of CD94/NKG2A.
Summary
SymbolMUC16
Namemucin 16, cell surface associated
Aliases FLJ14303; CA125 ovarian cancer antigen; ovarian cancer-related tumor marker CA125; ovarian carcinoma antigen ......
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MUC16 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMUC16
Namemucin 16, cell surface associated
Aliases FLJ14303; CA125 ovarian cancer antigen; ovarian cancer-related tumor marker CA125; ovarian carcinoma antigen ......
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MUC16 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9161.6780.0754
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.3970.646
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472.0220.567
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1030.795
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2590.67
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.5430.301
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MUC16 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14175023.526.50.153
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1036033.326.70.559
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4142521.43.61
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277374.154.819.30.108
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 014035.7-35.71
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275974.159.314.80.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21178182.4-1.41
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8662.5100-37.50.209
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131192.372.719.60.3
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91655.631.224.40.397
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 596033.326.70.58
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 475028.621.40.576
1329033130MelanomaallAnti-PD-1 (nivolumab) 382755.351.93.40.806
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22135053.8-3.81
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161462.55012.50.713
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.17.71.41
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610100-1000.143
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512200200.294
Summary
SymbolMUC16
Namemucin 16, cell surface associated
Aliases FLJ14303; CA125 ovarian cancer antigen; ovarian cancer-related tumor marker CA125; ovarian carcinoma antigen ......
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MUC16. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMUC16
Namemucin 16, cell surface associated
Aliases FLJ14303; CA125 ovarian cancer antigen; ovarian cancer-related tumor marker CA125; ovarian carcinoma antigen ......
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MUC16. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MUC16.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMUC16
Namemucin 16, cell surface associated
Aliases FLJ14303; CA125 ovarian cancer antigen; ovarian cancer-related tumor marker CA125; ovarian carcinoma antigen ......
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MUC16. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMUC16
Namemucin 16, cell surface associated
Aliases FLJ14303; CA125 ovarian cancer antigen; ovarian cancer-related tumor marker CA125; ovarian carcinoma antigen ......
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MUC16 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMUC16
Namemucin 16, cell surface associated
Aliases FLJ14303; CA125 ovarian cancer antigen; ovarian cancer-related tumor marker CA125; ovarian carcinoma antigen ......
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MUC16 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMUC16
Namemucin 16, cell surface associated
Aliases FLJ14303; CA125 ovarian cancer antigen; ovarian cancer-related tumor marker CA125; ovarian carcinoma antigen ......
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MUC16 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting MUC16.
ID Name Drug Type Targets #Targets
DB04964OregovomabBiotechMUC161